Literature DB >> 15882260

T-cell transcriptome analysis points up a thymic disorder in idiopathic nephrotic syndrome.

Hicham Mansour1, Lydie Cheval, Jean-Marc Elalouf, Jean-Christophe Aude, Maria-Alexandra Alyanakian, Béatrice Mougenot, Alain Doucet, Georges Deschênes.   

Abstract

BACKGROUND: Idiopathic nephrotic syndrome is a proteinuric disease secondary to the release of a nonidentified circulating glomerular permeability factor by T cells. Because specificities of T-cell activation in idiopathic nephrotic syndrome remain unknown, we evaluated transcriptional activation of T cells in nephrotic patients during proteinuria.
METHODS: Transcriptomes of CD2+ cells were analyzed by serial analysis of gene expression (SAGE) in a nephrotic child during proteinuria relapse and after remission, away from any immunosuppressive treatment. Expression of specific transcripts overexpressed during proteinuria relapse was compared by reverse transcription-polymerase chain reaction (RT-PCR) in CD2+ cells from 11 nephrotic patients during relapse and remission and 11 non nephrotic patients during infection and after recovery.
RESULTS: Differential analysis of CD2+ cell transcriptome identified >200 mRNA tags overexpressed during proteinuria relapse, including many T-cell markers. RT-PCR analysis of expression of specific transcripts indicated that (1) under remission conditions, nephrotic children displayed induction of four transcripts, including IKBKB, and repression of NFKBIA as compared to non nephrotic children after recovery, and (2) proteinuria relapse was associated with induction of L-selectin and T-lymphocyte maturation-associated protein, two markers of T-cell differentiation and recent emigrant/naive T cells.
CONCLUSION: Results indicate that circulating T cells from relapsing nephrotic patients include a significant population of low-mature cells while those from nephrotic patients in remission are characterized by constitutive activation of nuclear factor-kappaB (NF-kappaB), altogether suggesting a thymic dysregulation of apoptosis in nephrotic patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15882260     DOI: 10.1111/j.1523-1755.2005.00322.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  14 in total

1.  Cure of relapsing nephrosis by an allogeneic marrow graft for chronic myelogenous leukemia.

Authors:  Keisuke Sugimoto; Naoki Sakata; Shinsuke Fujita; Tomoki Miyazawa; Hitomi Nishi; Tsukasa Takemura; Mitsuru Okada
Journal:  Pediatr Nephrol       Date:  2013-02-23       Impact factor: 3.714

2.  Apolipoprotein AII levels are associated with the UP/UCr levels in idiopathic steroid-sensitive nephrotic syndrome.

Authors:  Takahiro Kanai; Takanori Yamagata; Takane Ito; Jun Odaka; Takashi Saito; Jun Aoyagi; Mariko Y Momoi
Journal:  Clin Exp Nephrol       Date:  2014-03-15       Impact factor: 2.801

3.  Rituximab therapy for steroid-dependent minimal change nephrotic syndrome.

Authors:  Rodney D Gilbert; Eleanor Hulse; Susan Rigden
Journal:  Pediatr Nephrol       Date:  2006-08-24       Impact factor: 3.714

Review 4.  Minimal change disease and idiopathic FSGS: manifestations of the same disease.

Authors:  Rutger J Maas; Jeroen K Deegens; Bart Smeets; Marcus J Moeller; Jack F Wetzels
Journal:  Nat Rev Nephrol       Date:  2016-10-17       Impact factor: 28.314

5.  Induction of remission following a single dose of rituximab alone in a patient with minimal change nephrotic syndrome.

Authors:  Nobuyuki Amemiya; Takashi Takei; Chiari Kojima; Hirohiko Nokiba; Mitsuyo Itabashi; Kosaku Nitta
Journal:  Clin Exp Nephrol       Date:  2011-08-09       Impact factor: 2.801

Review 6.  Physiopathology of idiopathic nephrotic syndrome: lessons from glucocorticoids and epigenetic perspectives.

Authors:  Valéry Elie; May Fakhoury; Georges Deschênes; Evelyne Jacqz-Aigrain
Journal:  Pediatr Nephrol       Date:  2011-06-28       Impact factor: 3.714

7.  Stem cell mobilization in idiopathic steroid-sensitive nephrotic syndrome.

Authors:  Hélène Lapillonne; Annelaure Leclerc; Tim Ulinski; Laurent Balu; Arnaud Garnier; Nathalie Dereuddre-Bosquet; Hervé Watier; Marie-Hélène Schlageter; Georges Deschênes
Journal:  Pediatr Nephrol       Date:  2008-05-06       Impact factor: 3.714

8.  Long-term outcome of children treated with rituximab for idiopathic nephrotic syndrome.

Authors:  Stéphanie Tellier; Karine Brochard; Arnaud Garnier; Flavio Bandin; Brigitte Llanas; Vincent Guigonis; Mathilde Cailliez; Christine Pietrement; Olivier Dunand; Sylvie Nathanson; Aurélia Bertholet-Thomas; Lydia Ichay; Stéphane Decramer
Journal:  Pediatr Nephrol       Date:  2013-01-23       Impact factor: 3.714

Review 9.  Idiopathic nephrotic syndrome: the EBV hypothesis.

Authors:  Claire Dossier; Agnès Jamin; Georges Deschênes
Journal:  Pediatr Res       Date:  2016-09-28       Impact factor: 3.756

10.  Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases.

Authors:  Vincent Guigonis; Aymeric Dallocchio; Véronique Baudouin; Maud Dehennault; Caroline Hachon-Le Camus; Mickael Afanetti; Jaap Groothoff; Brigitte Llanas; Patrick Niaudet; Hubert Nivet; Natacha Raynaud; Sophie Taque; Pierre Ronco; François Bouissou
Journal:  Pediatr Nephrol       Date:  2008-05-09       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.